middle.news
Syntara Advances Clinical Trials with FDA Backing and $8M Capital Boost
9:18am on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
Syntara Advances Clinical Trials with FDA Backing and $8M Capital Boost
9:18am on Monday 27th of July, 2026 AEST
Key Points
FDA supports ~100-patient Phase 2b amsulostat trial
$8 million placement extends cash runway to Q3 2027
Preliminary SNT-4728 data shows significant inflammation reduction
SNT-9465 hypertrophic scar trial over 60% recruited
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE